Attendee search 

Nuvo Research Inc. is a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10.

Nuvo's first commercialized pain product is Pennsaid®, a non-steroidal anti-inflammatory drug (NSAID), used to treat the signs and symptoms of osteoarthritis of the knee. Pennsaid is available by prescription in the United States, Canada and several European countries. Through the acquisition of ZARS Pharma, Inc. in May 2011, the Company broadened its pain portfolio with two approved products - Pliaglis® and Synera®.

Accucaps Industries specializes in soft gel formulations and operates a full R&D organization, developing and supporting projects from early research to life cycle management. We are continually engaged with potential partners in exploring how our broad therapeutic portfolio, formulation, clinical development and manufacturing expertise combined with strong customer relationships, can yield mutually beneficial business relationships.

Our Product Innovation team has developed technologies which may enhance bioavailability through advanced technologies incorporated into the design of various formulation solutions within soft gel capsules.  Some of these technologies may assist your organization in maintaining their leading position with their top products through additional lifecycle options.

Alberta’s life science sector is strong and vibrant. It is comprised of 130 bioindustry companies concentrated in health, medical device applications, industrial bioproducts and agriculture biotechnology that directly employ more than 4,700 people.

Alberta is home to three research intensive academic institutions:

University of Alberta (www.ualberta.ca)

University of Calgary (www.ucalgary.ca)

University of Lethbridge (www.uleth.ca)

EXCEPTIONAL PROVINCIAL SUPPORT

Alberta Enterprise Corporation - $100 million to stimulate venture capital

Polaris Awards - to attract world leading researchers ($20 million each)

Alberta Nanotechnology Strategy ($150 million)

Newly integrated research and innovation system

OUR AREAS OF EXPERTISE

Today we apply this impressive expertise and knowledge across a wide range of sectors with internationally renowned researchers and companies in:

Infectious Diseases

Cardiology

Neurobiology

Diabetes

Oncology

Obesity

Nanotechnology

Based in Toronto, Canada, DRI Capital Inc. is a life sciences industry-focused investment management firm with over US$2 billion under management that purchases drug royalties from universities, inventors, research institutes and pharmaceutical and biotechnology companies.  DRI Capital closed Drug Royalty II in April, 2010 with US$701 million in equity capital commitments, and a Co-Investment Fund in December, 2010 with an additional US$225 million in equity capital commitments.  Investors in Drug Royalty II and the Co-Investment Fund include corporate entities, public pension plans, 501(c)(3) entities, family offices and a sovereign wealth fund. Royalties recently acquired by DRI’s funds include those on Johnson and Johnson’s Remicade, Amgen and Pfizer’s Enbrel, Kyowa Kirin’s Regpara, and Biogen Idec and Elan’s Tysabri. 

Accucaps Industries specializes in soft gel formulations and operates a full R&D organization, developing and supporting projects from early research to life cycle management. We are continually engaged with potential partners in exploring how our broad therapeutic portfolio, formulation, clinical development and manufacturing expertise combined with strong customer relationships, can yield mutually beneficial business relationships.

Our Product Innovation team has developed technologies which may enhance bioavailability through advanced technologies incorporated into the design of various formulation solutions within soft gel capsules.  Some of these technologies may assist your organization in maintaining their leading position with their top products through additional lifecycle options.

Clinical stage development company which has leveraged a fibrosis and wound healing platform into a breadth of products where there is significant unmet medical need with no standard of care. Lead indication is in Ph II with additonal products entering the clinic within the next 6 to 8 months.

Based in Toronto, Canada, DRI Capital Inc. is a life sciences industry-focused investment management firm with over US$2 billion under management that purchases drug royalties from universities, inventors, research institutes and pharmaceutical and biotechnology companies.  DRI Capital closed Drug Royalty II in April, 2010 with US$701 million in equity capital commitments, and a Co-Investment Fund in December, 2010 with an additional US$225 million in equity capital commitments.  Investors in Drug Royalty II and the Co-Investment Fund include corporate entities, public pension plans, 501(c)(3) entities, family offices and a sovereign wealth fund. Royalties recently acquired by DRI’s funds include those on Johnson and Johnson’s Remicade, Amgen and Pfizer’s Enbrel, Kyowa Kirin’s Regpara, and Biogen Idec and Elan’s Tysabri.